长期COVID及其与神经退行性疾病的关联:发病,神经成像和治疗
Jinyang Zhao1, Fan Xia1, Xue Jiao2
1Department of Radiology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Frontiers in neurology
|April 19, 2024
概括
COVID-19可以通过慢性炎症和影响中枢神经系统的免疫反应显著影响神经退行性疾病. 分子成像有助于评估神经炎症和感染后的认知症状.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- 由SARS-CoV-2引起的COVID-19带来了全球性的挑战.
- 后急性COVID-19影响显著影响神经退行性疾病患者.
研究的目的:
- 探索与SARS-CoV-2中枢神经系统感染途径相关的神经退行性疾病的机制.
- 研究炎症和免疫反应在神经元损伤和长期COVID-19后果中的作用.
主要方法:
- 检查SARS-CoV-2中枢神经系统感染途径.
- 使用分子成像,特别是FDG-PET,来评估神经炎症.
- 量化神经炎症和精神病/认知症状之间的关系.
主要成果:
- 慢性炎症和异常免疫反应是COVID-19相关神经元损伤的关键因素.
- 在COVID-19期间增加的促炎细胞因子会影响患者的预后.
- 分子成像可以准确地评估COVID-19后的神经退行性疾病的严重程度.
结论:
- 积极的感染后炎症控制至关重要.
- 建议开发针对ACE2受体,ERK1/2和Ca2+的向疗法.
- 要了解SARS-CoV-2对神经退行症的影响,需要进一步研究中枢神经系统感染机制.
相关概念视频
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Disorders of the Nervous Tissue
1.3K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.3K
Long-term Potentiation
55.2K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
55.2K
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183


